For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Bimekizumab - Psoriasis
PAD Profile : Bimekizumab - Psoriasis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Etanercept
- Infliximab
- Ustekinumab (Psoriasis)
- Secukinumab
- Apremilast
- Ixekizumab
- Brodalumab (Psoriasis)
- Guselkumab (Psoriasis)
- Tildrakizumab
- Certolizumab pegol
- Risankizumab
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Pain (Chronic)
- Narcolepsy
- All
- Atopic dermatitis
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve bimekizumab as a treatment option for the treatment of severe plaque psoriasis in line with NICE TA723. The current Psoriasis high cost immunomodulator treatment pathway is available below.
Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.
Bimekizumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).
Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”